iothalamate-meglumine and Meningioma

Iopamidol (280 mgI/ml) was compared with Conray 60 (iothalmate meglumine, 282 mgI/ml) during selective and superselective cerebral arteriography. Twelve patients were examined, and a total of 51 selective injections were compared. Iopamidol produced significantly less pain and burning than Conray 60 and caused no patient motion.

Topics: Adult; Aged; Cerebral Angiography; Clinical Trials as Topic; Double-Blind Method; Facial Neoplasms; Female; Hemangioma; Humans; Intracranial Arteriovenous Malformations; Iopamidol; Iothalamate Meglumine; Iothalamic Acid; Male; Meningeal Neoplasms; Meningioma; Middle Aged

The nonionic contrast agent iohexol was compared with the ionic agent iothalamate for contrast enhancement of brain tumors and radiation brain damage in dogs. Tissue enhancement during infusion of contrast and 5, 10, 15 and 30 min later was measured using quantitative computed tomography. Blood iodine was measured using x-ray fluorescence. Peak contrast enhancement occurred during infusion in tumors and after 5 min in irradiated normal brain for both contrast agents. Absolute uptake of contrast in each lesion was the same for both agents when normalized to total grams of iodine administered. Blood iodine levels were slightly but not significantly higher using iohexol. The reduced osmotic load and similar contrast enhancement of lesions suggest that the nonionic contrast medium iohexol may be a useful agent for routine CT of the brain.

Topics: Animals; Brain; Brain Neoplasms; Dogs; Ependymoma; Iodine Radioisotopes; Iodobenzoates; Iohexol; Iothalamate Meglumine; Iothalamic Acid; Male; Meningeal Neoplasms; Meningioma; Radiation Injuries, Experimental; Tomography, X-Ray Computed; Triiodobenzoic Acids